Equity Overview
Price & Market Data
Price: $6.84
Daily Change: -$0.09 / 1.32%
Range: $6.76 - $7.08
Market Cap: $433,783,904
Volume: 26,237
Performance Metrics
1 Week: 6.88%
1 Month: -3.53%
3 Months: 12.32%
6 Months: -34.86%
1 Year: -56.87%
YTD: -6.56%
Company Details
Employees: 69
Sector: Health technology
Industry: Pharmaceuticals: other
Country: France
Details
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults and Phase 2b clinical trial of obefazimod in patients with Crohn's disease. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.